AbCellera Biologics
ABCL
12.83
-0.32
-2.43%
AbCellera Biologics
US · ABCL
#2215 by market cap
Listed 2020
12.83
-0.32
-2.43%
Live - 5344 symbols - heartbeat 242s ago
· 2026-10-08 08:30
Pre-market
12.60
-1.79%
After-hours
12.85
+0.16%
Overnight
12.81
-0.16%
- Market cap
- 4.16B
- P/E (TTM)i
- -23.76
- P/Bi
- 4.64
- EPSi
- -0.49
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on ABCL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 2.1 percentage points.
Institutional ownership
- Held by institutions
- 36.75% -2.15pp
- Institutions
- 161
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Individual/Insider21.64%
Hedge Fund16.29%
Mutual Fund13.78%
Public Company5.63%
Private Company0.61%
Family Office/Trust0.31%
Government Pension Fund0.12%
Other41.61%
Top holders as of 2026-04-01
Carl Hansen
17.60% · 57.03M sh
Baker Bros. Advisors LP
10.19% · 33.01M sh
Capital Research
4.19% · 13.59M sh
Two Sigma Investments, LP
3.22% · 10.44M sh
Veronique Lecault
2.97% · 9.61M sh
The Toronto-Dominion Bank
2.95% · 9.57M sh
UBS Asset Management
1.91% · 6.19M sh
Bank of America Corporation
1.90% · 6.14M sh
ArrowMark Colorado Holdings, LLC
1.27% · 4.11M sh
BlackRock
1.17% · 3.81M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 45 buys · 4 sells
| Name | Role | Stake |
|---|---|---|
| Carl Hansen | CEO, President & Chairperson | 17.60% |
| Veronique Lecault | Chief Operating Officer | 2.97% |
| Michael Hayden | Lead Independent Director | 0.46% |
| Stephen Quake | Independent Director | 0.34% |
| Andrew Booth | Chief Financial Officer | 0.19% |
| John Montalbano | Independent Director | 0.08% |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0.00% |
| Lynn Seely | Independent Director | -- |
| Wen-Chaun Lo | Independent Director | -- |
| Victor Sandor | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-23 | Michael Hayden | Lead Independent Director | Open Market Acquisition | +53,613 | $10.64 |
| 2026-08-17 | John Montalbano | Independent Director | Open Market Acquisition | +10,000 | $11.03 |
| 2026-08-13 | Andrew Booth | Chief Financial Officer | Private Acquisition | +37,200 | $10.32 |
| 2026-08-11 | Michael Hayden | Lead Independent Director | Open Market Acquisition | +46,387 | $10.37 |
| 2026-08-10 | Michael Hayden | Lead Independent Director | Other Disposition | -50,000 | -- |
| 2026-06-30 | Lynn Seely | Independent Director | Other Derivative Acquisition | +152,207 | $7.85 |
| 2026-06-30 | Victor Sandor | Independent Director | Other Derivative Acquisition | +152,207 | $7.85 |
| 2026-06-10 | Stephen Quake | Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-10 | Michael Hayden | Lead Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-10 | John Montalbano | Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-02 | Andrew Booth | Chief Financial Officer | Derivative Exercise and Retained | +250,000 | $0.19 |
| 2026-05-13 | John Montalbano | Independent Director | Open Market Acquisition | +20,000 | $4.77 |
| 2026-02-26 | Carl Hansen | CEO, President & Chairperson | Open Market Acquisition | +38,000 | $3.44 |
| 2026-02-26 | Andrew Booth | Chief Financial Officer | Open Market Acquisition | +42,600 | $3.42 |
| 2026-02-25 | Carl Hansen | CEO, President & Chairperson | Open Market Acquisition | +177,457 | $3.27 |
| 2025-12-31 | Carl Hansen | CEO, President & Chairperson | Other Derivative Acquisition | +2,106,505 | $3.42 |
| 2025-12-31 | Tryn Stimart | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | Other Derivative Acquisition | +539,265 | $3.42 |
| 2025-12-31 | Andrew Booth | Chief Financial Officer | Other Derivative Acquisition | +808,898 | $3.42 |
| 2025-12-31 | Veronique Lecault | Chief Operating Officer | Other Derivative Acquisition | +539,265 | $3.42 |
| 2025-12-17 | Carl Hansen | CEO, President & Chairperson | Other Disposition | -225,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:30:15 · For reference only, not investment advice and not tailored to your situation.